PI3Kδ Inhibition as a Potential Therapeutic Target in COVID-19

PI3Kδ Inhibition as a Potential Therapeutic Target in COVID-19

The spread of the novel human respiratory coronavirus (SARS-CoV-2) is a global public health emergency. There is no known successful treatment as of this time, and there is a need for medical options to mitigate this current epidemic. SARS-CoV-2 uses the angiotensin-converting enzyme 2 (ACE2) recept...

Full description

Bibliographic Details
Main Authors: Giuseppe Palma, Teresa Pasqua, Giovannino Silvestri, Carmine Rocca, Paola Gualtieri, Antonio Barbieri, Anna De Bartolo, Antonino De Lorenzo, Tommaso Angelone, Ennio Avolio, Gerardo Botti
Format: Article
Language:English
Published: Frontiers Media S.A. 2020-08-01
Series:Frontiers in Immunology
Subjects:
PI3K
COVID-19
inflammation
therapy
SARS-CoV-2
Online Access:https://www.frontiersin.org/article/10.3389/fimmu.2020.02094/full

Internet

https://www.frontiersin.org/article/10.3389/fimmu.2020.02094/full

Similar Items